Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06004947 · ClinicalTrials.gov registry record · Phase 1
A Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant Medications
A Phase 1 study of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT06004947 is a Phase 1 study of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis that has completed, run by Amgen. The registered enrollment target is 32 participants, roughly in line with the 32-participant average among 3 other Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT06004947, a Phase 1 study of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of this study will be to evaluate the drug-drug interaction potential of CCX168 with concomitant medications, as either a perpetrator or a victim, following oral administration of CCX168 to healthy participants.
Conditions Studied
Interventions
- DRUG Midazolam
- DRUG Celecoxib
- DRUG Itraconazole
- DRUG Rifampicin
- DRUG CCX168
Study Locations (1)
Arizona
- Celerion - Tempe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2016-01-14 |
| Est. Completion | 2016-06-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06004947
The ClinicalTrials.gov registry entry for NCT06004947 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 32-participant average among 3 other Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis trials with a reported enrollment target. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis appearing as the primary indexed condition, and to 5 interventions - of which Midazolam is the first listed.
NCT06004947 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.
Frequently Asked Questions
What is clinical trial NCT06004947 about?
NCT06004947 is a clinical study titled "A Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant Medications". The primary objective of this study will be to evaluate the drug-drug interaction potential of CCX168 with concomitant medications, as either a perpetrator or a victim, following oral administration of CCX168 to healthy participants.
What is the current status of trial NCT06004947?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2016-01-14. Estimated completion is 2016-06-10.
What conditions does trial NCT06004947 study?
This clinical trial studies the following conditions: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis.
What interventions are being tested in trial NCT06004947?
The interventions under investigation include: Midazolam (DRUG), Celecoxib (DRUG), Itraconazole (DRUG), Rifampicin (DRUG), CCX168 (DRUG).
Who is sponsoring clinical trial NCT06004947?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06004947 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM)
ACTIVE NOT RECRUITING · Phase 1
-
An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases
ACTIVE NOT RECRUITING · Phase 1
-
A Study in Healthy Volunteers to Evaluate the Pharmacokinetic Food Effect and Cardiac Safety of CCX168
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.